Lonza Group AG

Equities

LONN

CH0013841017

Biotechnology & Medical Research

Market Closed - Swiss Exchange Other stock markets 18:30:03 10/04/2026 +03			5-day change	1st Jan Change
515.00 ^CHF	+1.74%		+0.55%	-4.24%

04-01	Swiss stocks - Factors to watch on April 1	RE
03-25	STARLIMS Corporation agreed to acquire MODA Platform from Lonza Group AG	CI

Lonza to sell capsule and health ingredients business to Lone Star for $3.0 billion

Published on 03/06/2026 at 08:25 pm +03 - Modified on 03/06/2026 at 08:28 pm +03

Reuters

LONZA GROUP AG

+1.74%

Lonza to sell capsule and health ingredients business to Lone Star for $3.0 billion

March 6 (Reuters) - Lonza will sell its capsules and health ingredients business to private equity firm Lone Star Funds for an enterprise value of 2.3 billion Swiss francs ($3.0 billion), the Swiss contract drug manufacturer said on Friday.

The company has been seeking to exit the business since December 2024, with an aim to focus solely on its core contract drug manufacturing offering.

KEY DETAILS

- Lonza will receive upfront proceeds of 1.7 billion Swiss francs and retain a 40% stake in the business

- Total undiscounted proceeds are expected to be at or above 3 billion Swiss francs

- The transaction is expected to close in the second half of 2026

($1 = 0.7777 Swiss francs)

(Reporting by Bartosz Dabrowski in Gdansk; Editing by Kristen Donovan)

Latest news about Lonza Group AG

04-01	Swiss stocks - Factors to watch on April 1	RE
03-25	STARLIMS Corporation agreed to acquire MODA Platform from Lonza Group AG	CI
03-19	Swiss trade surplus at CHF 4.20 bln in February	RE
03-09	Lonza Extends Long-term Production Tie-up for Genetix's Gene Therapy	MT
03-09	Lonza Group and Genetix Biotherapeutics extend commercial manufacturing agreement for Zynteglo	RE
03-09	Lonza Group AG and Genetix Biotherapeutics, Inc. Extends Commercial Manufacturing Agreement for ZYNTEGLO	CI
03-09	Lonza Seeks M&A	CI
03-09	Lonza Group AG - Special Call
03-09	Lonza to Become Pure-play Pharma Contract Developer With CHF2.3 Billion Sale of Capsules, Ingredients Division	MT
03-09	Swiss stocks - Factors to watch on March 9	RE
03-09	Lonza Agrees CHF2.3 Billion Sale of Capsules, Ingredients Business to Conclude Transformation Plan	MT
03-06	Lone Star Fund XII, L.P., a fund managed by Lone Star Americas Acquisitions, Inc. entered into an agreement to acquire 60% stake in Capsules & Health Ingredients business of Lonza Group AG from Lonza Group AG for CHF 1.7 billion.	CI
03-06	Lonza to Offload Majority Stake in Capsule Business to Lone Star in $2.2 Billion Deal	DJ
03-06	Lonza to sell capsule and health ingredients business to Lone Star for $3.0 billion	RE
03-04	Octane Biotech Inc. agreed to acquire Personalized Medicine business from Lonza Group AG.	CI

Chart Lonza Group AG

Duration

Period

LONN: Dynamic Chart

Company Profile

Lonza Group AG is one of the world leaders of the contract development and manufacturing of pharmaceutical and biotechnology products. Net sales break down by family of products and services as follows: - biologics and bio-pharmaceuticals (55.9%): microbiological fermentation products, mammalian cell-based bio-pharmaceuticals, monoclonal antibodies, therapeutic proteins, etc.; - synthesis products (24.7%): chemopharmaceutical products, bioconjugates, small molecules, active pharmaceutical ingredients, complex intermediates, etc.; - specialised therapeutic products (15.8%): cell and gene therapies, synthetic therapeutic nucleic acids, oligonucleotides, microbial biological products, etc.; - others (3.6%).

Employees

20,000

Sector

Biotechnology & Medical Research

Calendar

05-12 - Ex-dividend date - 2.5 CHF

More about the company